
Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions Transcript
Kentaro Asakura
Corporate Officer, Head of Corporate Communications Deptt, Global Corporate Planning & Mngmt
Thank you for waiting, everybody. We’ll now start Daiichi Sankyo’s ESMO 2025 highlights. This is Ken Asakura from Corporate Communications, and I will be the moderator today. First, about the language for this event.
Presentation will be in English, and Q&A will be in both English and Japanese. Simultaneous interpretation is provided, so please click the interpretation icon at the bottom of the screen and select either English, Japanese or original audio. When original audio is selected, you will hear the original sound.
English presentation slides will be shown on the Zoom screen, as well as live streaming screen. The slides have been uploaded to IR presentation material page of Investors section on our corporate website, so please view or download as needed.
Our presenters for today are Dr. Ken Takeshita, our Head of Global R&D; and Dr. Abderrahmane Laadem, our Head of Late-Stage Clinical Development. We’ll take questions after the presentation. And please note that this event will be recorded.